Physician profile
Michael P Tonner
NPI 1740280122
$6,789.50
in general payments reported to CMS, 2019-2025
33 companies · $954 in 2025
The $954 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,829 · 2020: $1,014 · 2021: $684 · 2022: $204 · 2023: $638 · 2024: $468 · 2025: $954.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,042 · Education: $17.38.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,042.16 |
| Education | $17.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Veran Medical Technologies, INC. | $1,216.80 | 2019 | |
| Glaxosmithkline, LLC. | $995.09 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Astrazeneca Pharmaceuticals LP | $921.92 | 2019-2025 | Fasenra, Tezspire, Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $791.38 | 2019-2025 | Ofev, Jascayd |
| Philips North America LLC | $317.30 | 2019-2023 | |
| Mylan Specialty L.P. | $276.30 | 2019-2024 | Yupelri |
| Insmed, INC. | $226.85 | 2020-2025 | Arikayce |
| Harmony Biosciences LLC | $210.70 | 2020-2021 | |
| Grifols USA, LLC | $207.57 | 2019-2023 | Prolastin-C Liquid |
| United Therapeutics Corporation | $159.25 | 2023-2024 | Tyvaso |
| Genentech USA, INC. | $154.69 | 2019-2021 | |
| Verona Pharma, INC. | $150.32 | 2025 | Ohtuvayre |
| Electromed, INC. | $112.11 | 2019-2025 | Smartvest |
| Jazz Pharmaceuticals INC. | $96.26 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $91.22 | 2019-2021 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $88.96 | 2020-2021 | |
| Actelion Pharmaceuticals US, INC. | $86.00 | 2019-2021 | |
| Pulmonx Corporation | $84.71 | 2023-2025 | Zephyr Endobronchial Valve, Chartis Catheter, Zephyr Delivery Catheter |
| Ethicon INC. | $84.52 | 2025 | Monarch Platform |
| Shire North American Group INC | $81.97 | 2019 | |
| Resmed Corp | $75.79 | 2023 | |
| Circassia INC. | $56.58 | 2019-2020 | |
| Melinta Therapeutics, LLC | $46.10 | 2021 | |
| Merck Sharp & Dohme LLC | $44.52 | 2023-2025 | Zerbaxa, Recarbrio |
| Advanced Respiratory, INC | $40.45 | 2019 | |
| Eisai INC. | $30.44 | 2020 | |
| Regeneron Healthcare Solutions, INC. | $29.85 | 2023 | Dupixent |
| Tactile Systems Technology INC | $26.31 | 2023 | Flexitouch Plus, Entre Plus |
| Inogen, INC. | $23.26 | 2022 | |
| Arbor Pharmaceuticals, INC. | $22.53 | 2019 | |
| Amgen INC. | $16.13 | 2025 | Tezspire |
| Ambu INC. | $11.90 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $11.72 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Tonner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.